Q/C Technologies Files 8-K/A Amendment

TL;DR

QC Tech filed an 8-K/A amendment on director/officer changes as of Sept 30.

AI Summary

Q/C Technologies, Inc. filed an amendment (8-K/A) on October 6, 2025, reporting events as of September 30, 2025. The filing pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers. The company was formerly known as TNF Pharmaceuticals, Inc., MyMD Pharmaceuticals, Inc., and Akers Biosciences, Inc.

Why It Matters

This amendment to a previous filing provides updated information regarding changes in the company's board of directors and executive officers, which can impact corporate governance and strategic direction.

Risk Assessment

Risk Level: low — This filing is an amendment to a previous report and primarily concerns corporate governance and personnel changes, not immediate financial distress or significant operational shifts.

Key Players & Entities

• Q/C Technologies, Inc. (company) — Registrant
• TNF Pharmaceuticals, Inc. (company) — Former company name
• MyMD Pharmaceuticals, Inc. (company) — Former company name
• Akers Biosciences, Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share QCLS The Nasdaq Capital M

Filing Documents

• form8-ka.htm (8-K/A) — 39KB
• 0001493152-25-017104.txt ( ) — 204KB
• tnfa-20250930.xsd (EX-101.SCH) — 3KB
• tnfa-20250930_lab.xml (EX-101.LAB) — 33KB
• tnfa-20250930_pre.xml (EX-101.PRE) — 22KB
• form8-ka_htm.xml (XML) — 4KB

02 Departure of Directors or Certain Officers;

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 3, 2025 (the "Grant Date"), the Board of Directors (the "Board") of the Company approved grants to each of Joshua Silverman, the Company's Executive Chairman, Christopher Schriber, a director of the Company, Bill White, a director of the Company, Stephen Friscia, a director of the Company, Mitchell Glass, the Company's Chief Medical Officer and director of the Company, Gary Rauch, the Company's Vice President of Finance, and Bruce Bernstein, a director of the Company, of an aggregate of 225,000 RSUs consisting of: (i) 8,644 RSUs to Mr. Silverman, 2,161 RSUs to Mr. Schreiber, 2,161 RUSs to Mr. White, 2,161 RUSs to Mr. Friscia, 1,080 RSUs to Mr. Glass and 1,080 RSUs to Mr. Rauch (the "Initial Grants"), which Initial Grants were issued and fully vested on the Grant Date, and (ii) 91,356 RSUs to Mr. Silverman, 22,839 RSUs to Mr. Schreiber, 22,839 RSUs to Mr. White, 22,839 RSUs to Mr. Friscia, 11,420 RSUs to Mr. Glass, 11,420 RSUs to Mr. Rauch and 25,000 RSUs to Mr. Bernstein (the "Additional Grants"), which Additional Grants will be issued, and will fully vest upon, receipt of stockholder approval of an increase in the shares reserved and available under the Company's Q/C Technologies, Inc. 2021 Equity Incentive Plan (as amended, the "Plan"). The Initial RSUs and Additional RSUs were issued or will be issued, as applicable, pursuant to the Plan.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Q/C TECHNOLOGIES, INC. Date: October 6, 2025 By: /s/ Joshua Silverman Name: Joshua Silverman Title: Executive Chairman

View Full Filing

View this 8-K/A filing on SEC EDGAR